Protara Therapeutics Inc

NASDAQ:TARA  
23.62
-0.80 (-3.28%)
Earnings Announcements

Protara Therapeutics Announces Third Quarter 2020 Financial Results And Business Overview

Published: 11/12/2020 12:29 GMT
Protara Therapeutics Inc (TARA) - Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview.
Protara Therapeutics Inc - on Track to Complete Gmp Batch Runs in Mid-2021 to Confirm Comparability Between Tara-002 and Ok-432.
Protara Therapeutics Inc - Expect to Initiate Phase 1 Trial for Tara-002 in Patients With Non-muscle Invasive Bladder Cancer in 2021.
Protara Therapeutics Inc Qtrly Loss per Share $1.26.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.29

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.28

More details on our Analysts Page.